4568.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 04:35):

Stats
Dagens volum	3.05M
Gjennomsnittsvolum	4.31M
Markedsverdi	10 237.53B
EPS	¥0 ( 2024-04-25 )
Neste inntjeningsdato	( ¥19.29 ) 2024-07-29
Last Dividend	¥15.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	50.99
ATR14	¥5.69 (0.11%)

Volum Korrelasjon

Lang: 0.20 (neutral)

Kort: -0.27 (neutral)

Signal:(49.283) Neutral

Daiichi Sankyo Company, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Daiichi Sankyo Company, Korrelasjon - Valuta/Råvare

-0.39
( neutral )

-0.24
( neutral )

0.40
( neutral )

-0.31
( neutral )

0.00
( neutral )

0.16
( neutral )

Daiichi Sankyo Company, Økonomi

Annual	2023
Omsetning:	¥1 601.69B
Bruttogevinst:	¥1 186.37B (74.07 %)
EPS:	¥104.69

FY	2023
Omsetning:	¥1 601.69B
Bruttogevinst:	¥1 186.37B (74.07 %)
EPS:	¥104.69

FY	2022
Omsetning:	¥1 278.48B
Bruttogevinst:	¥914.95B (71.57 %)
EPS:	¥56.96

FY	2022
Omsetning:	¥1 044.89B
Bruttogevinst:	¥691.56B (66.19 %)
EPS:	¥34.94

Financial Reports:

No articles found.

Daiichi Sankyo Company, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥15.00 (N/A)	¥0 (N/A)	¥15.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Daiichi Sankyo Company, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.81 - Stable (3.81%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥4.08	2000-03-28
Last Dividend	¥15.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥443.25	--
Avg. Dividend % Per Year	0.00%	--
Score	4.04	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.81
Div. Directional Score	8.61	--

Next Divdend (Est)
(2024-08-05)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

4.04

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8056.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7309.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
6555.T	Ex Dividend Junior	2024-02-28	Semi-Annually	0.00%
5909.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
4569.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3817.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
3079.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
1949.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9936.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8955.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.125	1.500	7.49	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0580	1.200	8.07	9.68	[0 - 0.3]
returnOnEquityTTM	0.125	1.500	9.72	10.00	[0.1 - 1]
payoutRatioTTM	0.335	-1.000	6.65	-6.65	[0 - 1]
currentRatioTTM	3.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.522	0.800	5.75	4.60	[0.8 - 2.5]
cashRatioTTM	0.895	1.500	6.14	9.21	[0.2 - 2]
debtRatioTTM	0.0294	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	11.63	1.000	6.80	6.80	[3 - 30]
operatingCashFlowPerShareTTM	312.54	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	248.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0603	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.741	1.000	0.988	0.988	[0.2 - 0.8]
operatingProfitMarginTTM	0.132	1.000	9.36	9.36	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.89	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.463	0.800	-0.248	-0.199	[0.5 - 2]
Total Score				12.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	50.70	1.000	4.98	0	[1 - 100]
returnOnEquityTTM	0.125	2.50	9.82	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	248.50	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.942	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	312.54	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.335	1.500	6.65	-6.65	[0 - 1]
pegRatioTTM	-4.70	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.374	1.000	3.15	0	[0.1 - 0.5]
Total Score				4.81

Daiichi Sankyo Company,

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.